MRNS Stock Recent News

MRNS LATEST HEADLINES

MRNS Stock News Image - accesswire.com

NEW YORK, NY / ACCESSWIRE / June 17, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Marinus Pharmaceuticals, Inc. ("Marinus" or "the Company") (NASDAQ:MRNS) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Marinus securities between March 17, 2021 and May 7, 2024, inclusive (the "Class Period").

accesswire.com 2024 Jun 17
MRNS Stock News Image - businesswire.com

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Marinus Pharmaceuticals, Inc. (“Marinus” or the “Company”) (NASDAQ: MRNS) securities between March 17, 2021 and May 7, 2024, inclusive (the “Class Period”). Marinus investors have until August 5, 2024 to file a lead plaintiff motion. If you suffered a loss on your Mar.

businesswire.com 2024 Jun 17
MRNS Stock News Image - accesswire.com

LOS ANGELES, CA / ACCESSWIRE / June 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Marinus Pharmaceuticals, Inc. ("Marinus" or "the Company") (NASDAQ:MRNS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

accesswire.com 2024 Jun 17
MRNS Stock News Image - benzinga.com

Monday, Marinus Pharmaceuticals Inc MRNS announced topline results from the Phase 3 RAISE trial evaluating the safety and efficacy of intravenous (IV) ganaxolone for refractory status epilepticus (RSE).

benzinga.com 2024 Jun 17
MRNS Stock News Image - globenewswire.com

NEW YORK, June 17, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS)? Did you purchase your shares between March 17, 2021 and May 7, 2024, inclusive?

globenewswire.com 2024 Jun 17
MRNS Stock News Image - businesswire.com

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline results from the Phase 3 double-blind, randomized, placebo-controlled RAISE trial (NCT04391569) evaluating the safety and efficacy of intravenous (IV) ganaxolone for the treatment of refractory status epilepticus (RSE). RSE, in which prolonged continuous or rapidly recurring seizures do no.

businesswire.com 2024 Jun 17
MRNS Stock News Image - accesswire.com

NEW YORK, NY / ACCESSWIRE / June 16, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Marinus Pharmaceuticals, Inc. ("Marinus" or "the Company") (NASDAQ:MRNS) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Marinus securities between March 17, 2021 and May 7, 2024, inclusive (the "Class Period").

accesswire.com 2024 Jun 16
MRNS Stock News Image - globenewswire.com

NEW YORK, June 16, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) between March 17, 2021 and May 7, 2024, both dates inclusive (the “Class Period”), of the important August 5, 2024 lead plaintiff deadline in the securities class action first filed by the Firm.

globenewswire.com 2024 Jun 16
MRNS Stock News Image - accesswire.com

NEW YORK, NY / ACCESSWIRE / June 14, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Marinus Pharmaceuticals, Inc. ("Marinus" or "the Company") (NASDAQ:MRNS) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Marinus securities between March 17, 2021 and May 7, 2024, inclusive (the "Class Period").

accesswire.com 2024 Jun 14
MRNS Stock News Image - businesswire.com

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Marinus Pharmaceuticals, Inc. (“Marinus” or the “Company”) (NASDAQ: MRNS) securities between March 17, 2021 and May 7, 2024, inclusive (the “Class Period”). Marinus investors have until August 5, 2024 to file a lead plaintiff motion. Investors suffering losses on their Marinus investments are encouraged to contact the Law Offices of Howard G. S.

businesswire.com 2024 Jun 14
10 of 50